Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−12.04 USD
−6.91 M USD
0.00 USD
1.64 M
About Galmed Pharmaceuticals Ltd.
Sector
CEO
Allen Baharaff
Headquarters
Ramat Gan
Website
Founded
2000
ISIN
IL0011313900
FIGI
BBG005ZD02W1
Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of GLMD is 2.87 USD — it has increased by 4.36% in the past 24 hours. Watch Galmed Pharmaceuticals Ltd. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Galmed Pharmaceuticals Ltd. stocks are traded under the ticker GLMD.
GLMD stock has fallen by −3.04% compared to the previous week, the month change is a −28.25% fall, over the last year Galmed Pharmaceuticals Ltd. has showed a −22.85% decrease.
GLMD reached its all-time high on Jun 12, 2018 with the price of 4,868.36 USD, and its all-time low was 2.73 USD and was reached on Sep 4, 2024. View more price dynamics on GLMD chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
GLMD stock is 6.99% volatile and has beta coefficient of 2.16. Track Galmed Pharmaceuticals Ltd. stock price on the chart and check out the list of the most volatile stocks — is Galmed Pharmaceuticals Ltd. there?
Today Galmed Pharmaceuticals Ltd. has the market capitalization of 4.76 M, it has decreased by −4.44% over the last week.
Yes, you can track Galmed Pharmaceuticals Ltd. financials in yearly and quarterly reports right on TradingView.
Galmed Pharmaceuticals Ltd. is going to release the next earnings report on Mar 26, 2025. Keep track of upcoming events with our Earnings Calendar.
GLMD net income for the last quarter is −1.91 M USD, while the quarter before that showed −1.12 M USD of net income which accounts for −71.05% change. Track more Galmed Pharmaceuticals Ltd. financial stats to get the full picture.
No, GLMD doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 27, 2024, the company has 8.00 employees. See our rating of the largest employees — is Galmed Pharmaceuticals Ltd. on this list?
Like other stocks, GLMD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Galmed Pharmaceuticals Ltd. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Galmed Pharmaceuticals Ltd. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Galmed Pharmaceuticals Ltd. stock shows the sell signal. See more of Galmed Pharmaceuticals Ltd. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.